Skip to main content

Table 1 Patient characteristics and clinical status at baseline

From: The effect of financial incentives on patients’ motivation for treatment: results of “Money for Medication,” a randomised controlled trial

Variable Total (n = 169) Intervention group (n = 84) Control group (n = 85)
Age mean (SD), years 40.7 (9.8) 40.6 (9.4) 40.7 (10.2)
Gender, N (%)
 - Male 127 (75.1) 61 (72.6) 66 (77.6)
Patients > 50% medication adherence, N (%) 135 (79.9) 68 (80.0) 67 (79.8)
Place of treatment, N (%)
 - The Hague 46 (27.2) 18 (21.4) 18 (21.2)
 - Rotterdam 123 (72.8) 66 (78.6) 67 (78.8)
Substance use disorder, N (%) 94 (55.6) 48 (57.1) 46 (54.1)
Antipsychotic Medication side effects, mean (SD) 4,8 (4,0) 5,3 (4,0) 4,3 (3,9)
Illness insight; median (interquartile range) (range 1–7) 3 (1–4) 3 (1–4) 2 (1–4)
Health of the Nation Outcome Scales (HoNOS), N (%)
 - No motivational problems 136 (80.4) 66 (78.6) 70 (82.3)
 - Severe motivational problems 28 (16.6) 17 (20.2) 11 (12.9)
 - Item missing 5 (3.0) 1 (1.2) 4 (4.8)
Treatment Entry Questionnaire, (TEQ) N (%) 85 (50.3) 42 (50.0) 43 (50.6)
 - External motivation; mean (SD), (range 12–84) 18.4 (7.8) 17.6 (8.1) 19.0 (7.6)
 - Introjected motivation; mean (SD), (range 6–42) 18.7 (10.6) 19.3 (9.4) 18.2 (9.4)
 - Identified motivation; mean (SD), (range 9–63) 28.5 (10.0) 28.6 (10.9) 28.5 (9.2)